Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Doximity (DOCS) Cash & Equivalents (2021 - 2025)

Doximity (DOCS) has disclosed Cash & Equivalents for 5 consecutive years, with $209.6 million as the latest value for Q1 2025.

  • On a quarterly basis, Cash & Equivalents rose 116.58% to $209.6 million in Q1 2025 year-over-year; TTM through Mar 2025 was $209.6 million, a 116.58% increase, with the full-year FY2025 number at $209.6 million, up 116.58% from a year prior.
  • Cash & Equivalents was $209.6 million for Q1 2025 at Doximity, up from $184.2 million in the prior quarter.
  • In the past five years, Cash & Equivalents ranged from a high of $594.3 million in Q2 2021 to a low of $66.4 million in Q1 2021.
  • A 5-year average of $163.0 million and a median of $112.8 million in 2022 define the central range for Cash & Equivalents.
  • Peak YoY movement for Cash & Equivalents: crashed 81.48% in 2022, then skyrocketed 178.61% in 2023.
  • Doximity's Cash & Equivalents stood at $85.1 million in 2021, then soared by 60.39% to $136.5 million in 2022, then dropped by 9.79% to $123.1 million in 2023, then surged by 49.69% to $184.2 million in 2024, then rose by 13.77% to $209.6 million in 2025.
  • Per Business Quant, the three most recent readings for DOCS's Cash & Equivalents are $209.6 million (Q1 2025), $184.2 million (Q3 2024), and $96.8 million (Q1 2024).